In Brief: Torrent buys Elder, studies supporting claims must be relevant, common ingredient names on labels, enzyme supplement guidance
This article was originally published in The Tan Sheet
Executive Summary
Torrent buys Elder; studies supporting claims must match dose, form – NAD; labels must carry common ingredient names; street drug alternative claims; CRN, ETA publish enzyme guidance; EMA prioritizes 2014 work program; and natural personal care market nears $30 billion.
You may also be interested in...
Cardio Benefit Claims For Cardio Miracle Debunked Under NAD Scrutiny
Evolution Nutraceuticals will discontinue claims that Cardio Miracle prevents or reverses the risk of heart attack and stroke because the investigative unit of the Council of Better Business Bureaus determined is evidence was the known benefits of ingredients in the product rather than studies on the formula. Studies the firm offered looked at the role of ingredients arginine, citrulline and beet powder and other nitrate-rich vegetables in stimulating nitric oxide production within the body, not at whether they helped prevent heart attack and stroke.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.